🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are escalating around the world, with figures suggesting in excess of 82 million new cases per year. Particularly high rates are reported in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the face of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices currently available.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program showed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Approval

One new antibiotic, also known as a brand name, was cleared by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is also used to treat UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This milestone signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

As per data detailed in a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This places it at an equal footing with the typical regimen, which involves an injection and a pill. The study included over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the ability to make available and distribute the drug in a wide range of regions with limited resources.

Doctors on the front lines have voiced optimism. Access to a one-pill regimen like this is described as a "game-changer" for gonorrhoea control. This is deemed vital to reduce the burden of the disease for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.